IGFBP-3 proteolysis by plasmin, thrombin, serum: Heparin binding, IGF binding, and structure of fragments

American Journal of Physiology - Endocrinology and Metabolism

Volumn 271, Issue 3 34-3, 1996, Pages

  Booth, Barbara A ^a   Boes, Mary ^a   Bar, Robert S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

binding protein degradation; endothelium; insulin like growth factor; insulin like growth factor binding protein 3

Indexed keywords

HEPARIN BINDING PROTEIN; PLASMIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THROMBIN;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLUCOSE TRANSPORT; GLYCOSYLATION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; TARGET CELL; VASCULAR ENDOTHELIUM;

EID: 0029797428     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1996.271.3.e465     Document Type: Article

References (20)

1. Arai, T., A. Arai, W. H. Busby, Jr., and D. R. Clemmons. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology 135: 2358-2363, 1994.
2. Arai, T., A. Parker, W. Busby, Jr., and D. R. Clemmons. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J. Biol. Chem. 269: 20388-20393, 1994.
3. Bach, L. A., and M. M. Rechler. Insulin-like growth factor binding proteins. Diabetes Rev. 3: 38-61, 1995.
4. Bang, P., K. Brismar, and R. G. Rosenfeld. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J. Clin. Endocrinol. Metab. 78: 1119-1127, 1994.
5. Blat, C., J. Villaudy, and M. Binoux. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J. Clin. Invest. 93: 2286-2290, 1994.
6. Boes, M., B.A. Booth, A. Sandra, B. L. Dake, A. Bergold, and R. S. Bar. IGFBP-4 accounts for the unique connective tissue distribution of endothelial cell IGFBPs perfused through the isolated heart. Endocrinology 131: 327-330, 1992.
7. Booth, B. A., M. Boes, D. L. Andress, B. L. Dake, M. C. Kiefer, C. Maack, R. J. Linhardt, K. Bar, E. E. O. Caldwell, J. Weiler, and R. S. Bar. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul. 5: 1-17, 1995.
8. Campbell, P. G., J. F. Novak, T. B. Yanosick, and J. H. McMaster. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130: 1401-1412, 1992.
9. Claussen, M., J. Zapf, and T. Braulke. Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid. Endocrinology 134: 1964-1966, 1994.
10. Conover, C. A., J. E. Perry, and D. J. Tindall. Endogenous cathepsin D mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J. Clin. Endocrinol. Metab. 80: 987-993, 1995.
11. Fielder, P. J., R. G. Rosenfeld, H. C. B. Graves, K. Grandbois, C. A. Maack, S. Sawamura, Y. Ogawa, A. Sommer, and P. Cohen. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul. 1: 164-172, 1994.
12. Fowlkes, J. L., K. Suzuki, H. Nagase, and K. M. Thrailkill. Proteolysis of insulin-like growth factor binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology 135: 2810-2813, 1994.
13. Frost, V. J., V. M. Macaulay, J. A. H. Wass, and J. M. P. Holly. Proteolytic modificaton of insulin-like growth factor-binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes. J. Endocrinol. 138: 545-554, 1993.
14. Grimes, R. W., and J. M. Hammond. Proteolytic degradation of insulin-like growth factor (IGF)-binding protein-3 by porcine ovarian granulosa cells in culture: regulation by IGF-I. Endocrinology 134: 337-343, 1994.
15. Jones, J. I, and D. R. Clemmons. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16: 3-34, 1995.
16. Lalou, C., C. Silve, R. Rosato, B. Segovia, and M. Binoux. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 135: 2318-2326, 1994.
17. Lee, C. Y., and M. M. Rechler. A major portion of the 150-kilodalton insulin-like growth factor-binding protein (IGFBP) complex in adult rat serum contains unoccupied, proteolytically nicked IGFBP-3 that binds IGF-II preferentially. Endocrinology 136: 668-678, 1995.
18. Moser, D. R., W. L. Lowe, Jr., B. L. Dake, B. A. Booth, M. Boes, D. R. Clemmons, and R. S. Bar. Endothelial cells express insulin-like growth factor-binding proteins 2 to 6. Mol. Endocrinol. 6: 1805-1814, 1992.
19. Schoen, R., J. Waldbillig, G. Searcy, S. J. Gaudet, B. E. Jones, G. J. Chader, and P. Moshyedi. Identification and partial characterization of a proteinase specific for insulin-like growth factor binding protein-3 in aqueous and vitreous humors. Curr. Eye Res. 14: 127-135, 1995.
20. Shimasaki, S., and N. Ling. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog. Growth Factor Res. 3: 243-266, 1991.